• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cholesterol, children, and heart disease: an analysis of alternatives.

作者信息

Berwick D M, Cretin S, Keeler E

出版信息

Pediatrics. 1981 Nov;68(5):721-30.

PMID:6796932
Abstract

Cost-effectiveness analysis is used to compare proposed cholesterol control programs. The analysis employs estimates of such biologic variables as effect of diet on cholesterol level, stability of level, and change in morbidity with level. Sensitivity analysis identifies the biologic and behavioral uncertainties that most critically affect policy choices. At a discount rate of 5%, a cholesterol-screening program for all 10-year-old children would cost about 10,000 per year of life saved. Rescreening would not improve efficiency. Targeted screening a high-risk children could improve efficiency by 25%, but would benefit only one sixth as many people. Community-wide interventions without screening may be more efficient by a factor of 3. The cost per year of life saved is most affected by the rate of discount and the dollar cost of changing behavior, but is insensitive to stability of cholesterol rank order and to the cost of screening.

摘要

相似文献

1
Cholesterol, children, and heart disease: an analysis of alternatives.
Pediatrics. 1981 Nov;68(5):721-30.
2
Cost effectiveness of work-site cholesterol screening and intervention programs.
J Occup Med. 1992 Jun;34(6):642-9.
3
Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.澳大利亚背景下低剂量螺旋CT(计算机断层扫描)筛查肺癌的成本效益分析。
Lung Cancer. 2005 May;48(2):171-85. doi: 10.1016/j.lungcan.2004.11.001. Epub 2005 Jan 4.
4
Cost-effectiveness of screening for hereditary hemochromatosis.遗传性血色素沉着症筛查的成本效益
Arch Intern Med. 1994 Apr 11;154(7):769-76.
5
Costs and health consequences of cholesterol screening for asymptomatic older Americans.对无症状美国老年人进行胆固醇筛查的成本与健康后果
Arch Intern Med. 1991 Jun;151(6):1089-95.
6
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.发展中国家的乳腺癌筛查政策:印度的成本效益分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1290-300. doi: 10.1093/jnci/djn292. Epub 2008 Sep 9.
7
Cost-effectiveness analysis of screening for celiac disease in the adult population.成人乳糜泻筛查的成本效益分析。
Med Decis Making. 2006 May-Jun;26(3):282-93. doi: 10.1177/0272989X06289012.
8
The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.对男性进行衣原体筛查以预防女性盆腔炎的项目成本及成本效益。
Sex Transm Dis. 2008 Nov;35(11 Suppl):S66-75. doi: 10.1097/OLQ.0b013e31818b64ac.
9
High participation rates are not necessary for cost-effective colorectal cancer screening.高参与率并非具有成本效益的结直肠癌筛查所必需的。
J Med Screen. 2005;12(2):96-102. doi: 10.1258/0969141053908276.
10
Cost-effectiveness of HIV screening in acute care settings.急性护理环境中HIV筛查的成本效益
Arch Intern Med. 1996 Feb 26;156(4):394-404.

引用本文的文献

1
Temporal trends in lipid screening and therapy among youth from 2002 to 2012.2002年至2012年间青少年血脂筛查与治疗的时间趋势。
J Clin Lipidol. 2015 Sep-Oct;9(5 Suppl):S77-87. doi: 10.1016/j.jacl.2015.06.014. Epub 2015 Jul 9.
2
Handling uncertainty in cost-effectiveness models.处理成本效益模型中的不确定性。
Pharmacoeconomics. 2000 May;17(5):479-500. doi: 10.2165/00019053-200017050-00006.
3
Resource utilisation in the management of dyslipidaemia.血脂异常管理中的资源利用
Pharmacoeconomics. 1998;14 Suppl 3:11-8. doi: 10.2165/00019053-199814003-00002.
4
Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.用于冠状动脉疾病一级和二级预防的降脂药物的药物经济学
Pharmacoeconomics. 1999 Jan;15(1):47-74. doi: 10.2165/00019053-199915010-00004.
5
Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.全科医疗中胆固醇相关干预措施的经济学评估。证据评估。
J Epidemiol Community Health. 1998 Sep;52(9):586-94. doi: 10.1136/jech.52.9.586.
6
Cost effectiveness of coronary heart disease prevention strategies in adults.成人冠心病预防策略的成本效益
Pharmacoeconomics. 1998 Jul;14(1):27-48. doi: 10.2165/00019053-199814010-00004.
7
Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.高胆固醇血症药物治疗的成本效益:文献综述
Pharmacoeconomics. 1992 Jul;2(1):34-42. doi: 10.2165/00019053-199202010-00005.
8
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.辛伐他汀:对其在高胆固醇血症及冠心病预防中的成本效益进行的药物经济学评估。
Pharmacoeconomics. 1992 Feb;1(2):124-45. doi: 10.2165/00019053-199201020-00009.
9
The reliability of cost-utility estimates in cost-per-QALY league tables .成本效益分析联盟表中成本效用估计的可靠性。
Pharmacoeconomics. 1993 May;3(5):345-53. doi: 10.2165/00019053-199303050-00002.
10
Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis.对献血者进行人类免疫缺陷病毒抗体筛查:成本效益分析。
Am J Public Health. 1988 Apr;78(4):450-4. doi: 10.2105/ajph.78.4.450.